Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PMCC-COE-KMA CAR T-cells |
| Synonyms | |
| Therapy Description |
Limited information is currently available on PMCC-COE-KMA CAR T-cells, putative T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting Kappa Myeloma Antigen (KMA) (May 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PMCC-COE-KMA CAR T-cells | Limited information is currently available on PMCC-COE-KMA CAR T-cells, putative T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting Kappa Myeloma Antigen (KMA) (May 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07541391 | Phase I | PMCC-COE-KMA CAR T-cells | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease (KOALA) | Not yet recruiting | AUS | 0 |